Acarbose

• Type 2 Diabetes Mellitus
• Postprandial Hyperglycemia
• Prediabetes (prevention)

Acarbose (Precose) is an oral alpha-glucosidase inhibitor used as adjunctive therapy in type 2 diabetes, particularly for patients whose blood sugar climbs sharply after meals. Because it works locally in the gut rather than systemically on insulin, it carries no risk of hypoglycemia when used alone — making it a reasonable option for select older adults, patients who have not tolerated other agents, or patients in whom postprandial glucose excursions dominate the glycemic picture even when fasting numbers look acceptable. It has been available since the 1990s and has accumulated decades of safety data, and remains relevant in modern algorithms despite the rise of newer oral agents.

Mechanism of Action

Acarbose competitively inhibits pancreatic alpha-amylase and the membrane-bound alpha-glucosidase enzymes (sucrase, maltase, isomaltase, glucoamylase) lining the brush border of the small intestine. These enzymes normally cleave starches and disaccharides into absorbable monosaccharides — primarily glucose. By delaying that final breakdown step, acarbose flattens the postprandial glucose curve without altering insulin secretion or peripheral insulin sensitivity. Undigested carbohydrate continues into the colon where bacterial fermentation produces gas, short-chain fatty acids, and the loose stools and bloating that limit tolerability for many patients.

Unlike most oral diabetes medications, acarbose's pharmacology is intentionally local. Less than 2% of an oral dose reaches systemic circulation, which is why systemic toxicities are uncommon. Renal handling matters mostly because of accumulation in the gut wall and bowel lumen rather than plasma. Because acarbose targets carbohydrate digestion specifically, its glycemic benefit is greatest in patients eating a higher-carbohydrate diet such as the typical American diet rich in bread, rice, pasta, and starchy vegetables. Patients on very low-carbohydrate eating patterns will see minimal effect — there is little substrate left for the enzyme to act on, and the drug becomes essentially inert.

A secondary effect of slower carbohydrate absorption is reduced postprandial insulin demand. This may be one reason acarbose has shown small cardiovascular benefits in some trials: postprandial hyperglycemia is independently associated with vascular inflammation and endothelial dysfunction, and blunting these spikes may translate into reduced atherogenesis over time. The mechanistic story remains incompletely worked out, but the population-level signal is real.

Clinical Use

Acarbose typically lowers HbA1c by 0.5–0.8 percentage points — a more modest effect than metformin or the newer SGLT2 inhibitors such as empagliflozin and dapagliflozin, and substantially less than GLP-1 receptor agonists like semaglutide or liraglutide. For most patients with newly diagnosed type 2 diabetes, current ADA standards still favor metformin as first-line therapy, with acarbose reserved for add-on use, metformin intolerance, or specific scenarios where postprandial spikes dominate. The American Diabetes Association updates these recommendations annually and the AAFP diabetes resources provide a primary-care-focused perspective.

The drug also has a documented role in prediabetes; the STOP-NIDDM trial showed reduced progression to overt diabetes and a signal toward reduced cardiovascular events in glucose-intolerant patients. Patients on combination therapy with sulfonylureas like glipizide, glimepiride, or glyburide, or with insulin such as insulin glargine and insulin lispro, may experience hypoglycemia. When low blood sugar occurs in this context, it must be treated specifically with oral glucose (dextrose tablets or gel) — table sugar will not work because acarbose blocks sucrose breakdown into glucose and fructose. This counseling point cannot be skipped.

Acarbose also has a small niche in patients with reactive hypoglycemia after gastric bypass, where its ability to slow carbohydrate absorption blunts both the early hyperglycemic surge and the rebound hypoglycemia 1–3 hours later. The closely related agent miglitol shares the same drug class and is used similarly. For patients who need additional oral therapy beyond metformin, alternative agents in different classes include the DPP-4 inhibitors sitagliptin, linagliptin, saxagliptin, and alogliptin; the meglitinides repaglinide and nateglinide; the thiazolidinedione pioglitazone; and the colesevelam (colesevelam) for patients with concurrent dyslipidemia.

How to Take It

Take acarbose with the first bite of each main meal. Swallowing it before food sits in the stomach blunts efficacy because the enzyme needs to encounter substrate while the drug is present; taking it after the meal is too late to inhibit digestion. If a meal is skipped, skip the dose. There is no benefit — and increased GI distress — to dosing without food.

Expect bloating, flatulence, and loose stools during the first few weeks. These symptoms are dose-related and almost always improve with time as the colonic microbiome adapts to processing additional fermentable carbohydrate. Starting low (25 mg once daily with the largest meal) and titrating slowly over 4–8 weeks dramatically improves tolerability compared with an aggressive three-times-daily start. Many practitioners stay at 25 mg three times daily for a month before considering 50 mg three times daily. Store at room temperature and keep tablets dry — humidity and heat shorten shelf life, which matters in the Florida climate.

Patients on insulin or sulfonylureas should carry glucose tablets (not candy or juice with sucrose) for hypoglycemia and tell every clinician — including dentists and emergency room staff — that they take acarbose, because the drug also delays the absorption of sucrose-based oral rehydration solutions. A medical-alert bracelet noting the diabetes regimen is reasonable for patients on combination therapy.

Diet and lifestyle remain the foundation of type 2 diabetes management regardless of pharmacotherapy choice. The article on eating out with diabetes and our pinellas county diabetes prevention guide reinforce the behavioral framework that makes any medication work better. The Mediterranean diet pattern is associated with improved glycemic control and cardiovascular outcomes in diabetes, and aligns well with acarbose's pharmacology because legumes, vegetables, and whole grains slow carbohydrate absorption naturally. During summer in Florida, glycemic management can shift unpredictably as activity, hydration, and meal patterns change — see diabetes and Florida heat management for practical strategies that complement medication adjustments. The article on blood sugar spikes — causes and prevention explains the postprandial glucose physiology that acarbose targets directly.

Monitoring and Follow-Up

Check HbA1c every 3 months until at goal, then every 6 months. Because acarbose has been associated with rare elevations in transaminases — particularly at doses above 100 mg three times daily — liver function tests should be obtained at baseline and every 3 months during the first year of treatment, then periodically thereafter. The article on understanding blood work and lab panels outlines what an AST/ALT pattern looks like and when isolated transaminase elevations warrant action.

Fingerstick glucose patterns matter more than fasting numbers with this drug; postprandial readings 1–2 hours after meals demonstrate whether acarbose is working. Patients who have access to continuous glucose monitoring will see the postprandial flattening in real time — often a powerful motivator for continued adherence. Renal function should be checked yearly because acarbose accumulates when serum creatinine exceeds 2 mg/dL. Iron and vitamin B12 status are worth periodic review since carbohydrate malabsorption may affect overall nutrition. The understanding A1c article helps patients interpret their own numbers, and our annual physical guide walks through what a comprehensive diabetes review visit should include. For patients on multiple medications, periodic medication reconciliation is critical to avoid duplicate therapy or dangerous interactions.

Special Populations

Elderly patients tolerate acarbose reasonably well from a glycemic-safety standpoint — the absence of hypoglycemia risk is appealing, especially in frail patients where a sulfonylurea-induced low could be devastating and lead to falls or hospitalization — but the gastrointestinal symptoms are often the limiting factor and may worsen pre-existing constipation, diverticular disease, or fecal incontinence. Patients with inflammatory bowel disease (Crohn disease, ulcerative colitis), chronic intestinal absorptive disorders, or partial bowel obstruction should not take this medication. Patients recovering from gastrointestinal surgery require individualized assessment.

For patients planning pregnancy, insulin remains the preferred agent for diabetes management because of the longest safety record. Pediatric data are insufficient to support routine use under age 18. In renal impairment with creatinine above 2 mg/dL, avoid the drug entirely because of accumulation in gut tissues despite minimal systemic absorption. Patients with cirrhosis need cautious monitoring of liver enzymes given baseline elevation, although the drug is not absolutely contraindicated. Patients on warfarin should have INR monitored more closely after starting acarbose because reduced carbohydrate absorption can subtly affect vitamin K status and anticoagulation stability.

When to Contact Your Doctor

Call promptly for: yellowing of the skin or eyes, dark urine, persistent right-upper-quadrant abdominal pain (possible hepatotoxicity); severe persistent diarrhea or sustained vomiting; abdominal distension with inability to pass gas or stool (consider ileus or, very rarely, pneumatosis cystoides intestinalis); or signs of hypoglycemia such as shakiness, sweating, confusion, palpitations, or fainting when used with insulin or sulfonylureas. Mild gas and bloating do not require a call but should be reported at your next visit if they fail to improve over the first month. Authoritative drug information is available at MedlinePlus and the FDA prescribing information.

If you have questions about acarbose or your diabetes treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.